Johnson & Johnson (NYSE:JNJ) recently experienced a 12% price increase over the last quarter, largely driven by significant ...

Belgian biotech Agomab Therapeutics (Nasdaq: AGMB) has reported positive interim results from its Phase IIa STENOVA trial of ...

Agomab Therapeutics NV (‘Agomab’) today announced positive interim results from 44 patients completing treatment in the ongoing STENOVA1 Phase 2a clinical trial for AGMB-129, an oral gastro-intestinal ...

Positive preliminary data from all five single ascending dose (SAD) cohorts and first three completed multiple ascending dose (MAD) cohorts ...

“The positive interim data for the STENOVA Phase ... unmet medical need that exists in the field of Fibrostenosing Crohn’s disease.” AGMB-129 is an investigational drug and not approved ...

HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced promising topline data from its Phase 2b ANTHEM-UC clinical trial evaluating icotrokinra (JNJ-2113) as a treatment for moderately to severely active ...

RedHill Biopharma (RDHL) announced plans to advance its groundbreaking late-stage program for Crohn’s disease, or CD, with initiation of an ...

Agomab Therapeutics NV (Agomab) has announced positive interim results from 44 patients completing treatment in the ongoing ...

(RTTNews) - Johnson & Johnson (JNJ) announced Monday positive topline results from ... in adults with moderately to severely active ulcerative colitis (UC). The study met its primary endpoint ...

Following initial positive results shared by Teva and Sanofi in December 2024, new data shows duvakitug (TEV’574/SAR447189) ...

Johnson & Johnson said that its mid-stage study of icotrokinra, for the treatment of moderate to severe active ulcerative ...

Drinking two small glasses of cherry juice daily may help reduce gut inflammation and improve the quality of life for people ...